What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and ...

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...

This special issue of CURE Lung Cancer takes a deeper dive into ALK-positive non-small cell lung cancer. In this special issue of CURE, we examine some of the latest developments in the treatment of ...

The goal is to find cures for ALK- positive lung cancer by targeting residual disease that remains after initial treatment. ALK Positive was founded on the principle that funding innovative, ...

A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...

First endorsed 11 years ago for anaplastic lymphoma kinase (ALK)-positive lung cancer, Pfizer’s Xalkori is being surpassed in that indication by the company’s own Lorbrena and Takeda’s Alunbrig. But ...

Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. Background: A small subset of human lung cancer harbors the fusion of the gene for echinoderm ...

Is Zykadia Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Zykadia is used for NSCLC that ...